 |
2 Diseases |  |
0 Trials |
|
0 Trials |  |
110 News |  |
- | ZEMBRACE SymTouch (sumatriptan succinate) / Tonix
Journal: Select autosomal dominant DFNA11 deafness mutations activate Myo7A in epithelial cells. (Pubmed Central) - Sep 30, 2024
Our findings reveal that Myo7A is regulated by specific IQ motifs within its lever arm, and that this regulation can function at least partially independent of its tail sequence. Importantly, we demonstrate that many of the DFNA11 deafness mutations reported in patients activate Myo7A targeting, providing a potential explanation for the autosomal dominant genetics of this form of deafness.
- ZEMBRACE SymTouch (sumatriptan succinate) / Tonix
Sumatriptan Induced Ischemic Colitis (Exhibit Hall) - Jul 29, 2023 - Abstract #ACG2023ACG_700;
For any individual on medication for migraine experiencing abdominal symptoms, a high index of suspicion needed for sumatriptan related ischemic colitis. Figure: Sumatriptan induced Ischemic Colitis - Gross, Microscopic and Imaging pictures
- | ONZETRA Xsail (sumatriptan intranasal) / Otsuka, Tosymra (intranasal sumatriptan) / Sawai Pharma, Neurelis, ZEMBRACE SymTouch (sumatriptan succinate) / Sawai Pharma
Journal: Comparison table: Triptans. (Pubmed Central) - Jun 6, 2023
Figure: Sumatriptan induced Ischemic Colitis - Gross, Microscopic and Imaging pictures No abstract available
- | Journal: Drugs for migraine. (Pubmed Central) - Jun 6, 2023
No abstract available No abstract available
- | ZEMBRACE SymTouch (sumatriptan succinate) / Sawai Pharma
Journal, Next-generation sequencing: Identification of novel missense mutation related with non-syndromic sensorineural deafness, DFNA11 in korean family by NGS. (Pubmed Central) - Jan 12, 2023
No abstract available This study is the first to report pathogenic mutations within MYO7A gene in Korean family and our data would facilitate diagnosing the primary cause of hereditary hearing loss in Korean.
- | ZEMBRACE SymTouch (sumatriptan succinate) / Sawai Pharma
Biomarker, Journal, Next-generation sequencing: Novel compound heterozygous synonymous and missense variants in the MYO7A gene identified by next-generation sequencing in a Chinese family with nonsyndromic hearing loss. (Pubmed Central) - Sep 29, 2022
We reported a novel missense (c.5994G > T) and identified, for the first time, a novel pathogenic synonymous (c.2904G > A) variant within MYO7A in a patient with DFNB2. These findings enrich our understanding of the MYO7A variant spectrum of DFNB2 and can contribute to accurate genetic counseling and diagnosis of NSHL patients.
- | ZEMBRACE SymTouch (sumatriptan succinate) / Sawai Pharma
Journal, Heterogeneity: Clinical Heterogeneity Associated with MYO7A Variants Relies on Affected Domains. (Pubmed Central) - Apr 24, 2022
MYO7A variants are associated with DFNA11, a subtype of ADHL...Audiological differences among individuals correspond to specific domains which contain the variants. Therefore, appropriate rehabilitation is needed, particularly for patients with late-onset familial hearing loss.
- || ZEMBRACE SymTouch (sumatriptan succinate) / Sawai Pharma
Clinical, Journal: Auditory Outcome after Cochlear Implantation in Children with DFNB7/11 Caused by Pathogenic Variants in TMC1 Gene. (Pubmed Central) - Jul 24, 2021
Therefore, appropriate rehabilitation is needed, particularly for patients with late-onset familial hearing loss. Our results do not support the variable auditory outcome reported in the literature, which may be affected by several social and environmental factors and by the genetic background.
- || Review, Journal: Acute Treatment of Migraine: What has Changed in Pharmacotherapies? (Pubmed Central) - Jun 22, 2021
These 5-HT receptor agonists and CGRP receptor antagonists did not cause vasoconstriction, offering advantages over the current mainstay of specific acute migraine treatment. Overall, these new agents have expanded the available acute therapies for migraine treatment and will likely change the strategy with which we treat patients with migraine in the future.
- | ZEMBRACE SymTouch (sumatriptan succinate) / Sawai Pharma
Journal: The p.R206C Mutation in MYO7A Leads to Autosomal Dominant Nonsyndromic Hearing Loss. (Pubmed Central) - Mar 31, 2021
The recurrent p.R206C variant in MYO7A is pathogenic and is likely in a mutation hot spot or due to a founder effect. Reports of such rare variants in multiple patients or families may facilitate exploitation of its pathogenicity.
- | Botox (onabotulinumtoxin A) / GSK, AbbVie
Journal: Drugs for Migraine. (Pubmed Central) - Jan 23, 2021
Reports of such rare variants in multiple patients or families may facilitate exploitation of its pathogenicity. No abstract available
- | Ubrelvy (ubrogepant) / AbbVie, Reyvow (lasmiditan) / Eli Lilly
Journal: Lasmiditan (Reyvow) and ubrogepant (Ubrelvy) for acute treatment of migraine. (Pubmed Central) - Sep 16, 2020
No abstract available No abstract available
- sumatriptan succinate / Generic mfg., ZEMBRACE SymTouch (sumatriptan succinate) / Sawai Pharma
[VIRTUAL] Treatment Outcomes for Oral, Subcutaneous and Intranasal Forms of Sumatriptan: Survey Results from Migraine in America Symptoms and Treatment (MAST) Study () - Jul 15, 2020 - Abstract #AHS2020AHS_283;
The proportion of participants achieving complete and meaningful relief of pain and associated symptoms was highest for subcutaneous, intermediate for oral and lowest for intranasal triptan users. Among responders, a higher proportion of participants achieved relief within one hour with intranasal vs. subcutaneous triptans followed by oral triptans.
- || ZEMBRACE SymTouch (sumatriptan succinate) / Sawai Pharma
Clinical, Journal: Clinical Profiles of DFNA11 at Diverse Stages of Development and Aging in a Large Family Identified by Linkage Analysis. (Pubmed Central) - Feb 26, 2020
We revealed that hearing loss at high frequencies was mainly noted in early developmental stages and that thresholds increased more rapidly in the low frequency range, resulting in changes in audiometric configuration. Deterioration of distortion product otoacoustic emissions (DPOAE) before the elevation of hearing thresholds was considered as a clinical feature of DFNA11.
- | ZEMBRACE SymTouch (sumatriptan succinate) / Tonix
Trial completion: RESTOR: DFN-11 Injection in Episodic Migraine With or Without Aura (clinicaltrials.gov) - Jul 26, 2018
P3, N=268, Completed, Sponsor: Dr. Reddy's Laboratories Limited
Deterioration of distortion product otoacoustic emissions (DPOAE) before the elevation of hearing thresholds was considered as a clinical feature of DFNA11. Active, not recruiting --> Completed
- ||| ZEMBRACE SymTouch (sumatriptan succinate) / Tonix
Trial completion date: RESTOR: DFN-11 Injection in Episodic Migraine With or Without Aura (clinicaltrials.gov) - Mar 3, 2018
P3, N=268, Active, not recruiting, Sponsor: Dr. Reddy's Laboratories Limited
Active, not recruiting --> Completed Trial completion date: Nov 2017 --> Mar 2018
- ||||| ZEMBRACE SymTouch (sumatriptan succinate) / Tonix
Enrollment closed: RESTOR: DFN-11 Injection in Episodic Migraine With or Without Aura (clinicaltrials.gov) - Mar 13, 2017
P3, N=268, Active, not recruiting, Sponsor: Dr. Reddy's Laboratories Limited
Trial completion date: Nov 2017 --> Mar 2018 Recruiting --> Active, not recruiting
- |||| ZEMBRACE SymTouch (sumatriptan succinate) / Tonix
Trial primary completion date: RESTOR: DFN-11 Injection in Episodic Migraine With or Without Aura (clinicaltrials.gov) - Mar 3, 2017
P3, N=266, Recruiting, Sponsor: Dr. Reddy's Laboratories Limited
Recruiting --> Active, not recruiting Trial primary completion date: Feb 2017 --> Jun 2017
- ZEMBRACE SymTouch (sumatriptan succinate) / Tonix
Enrollment change, Trial termination: Pilot Study of DFN-11 Injection in Medication Overuse Headache (clinicaltrials.gov) - Dec 20, 2016
P2, N=9, Terminated, Sponsor: Dr. Reddy's Laboratories Limited
Trial primary completion date: Feb 2017 --> Jun 2017 N=20 --> 9 | Recruiting --> Terminated
- |||| ZEMBRACE SymTouch (sumatriptan succinate) / Tonix
Trial primary completion date: RESTOR: DFN-11 Injection in Episodic Migraine With or Without Aura (clinicaltrials.gov) - Aug 8, 2016
P3, N=266, Recruiting, Sponsor: Dr. Reddy's Laboratories Limited
N=20 --> 9 | Recruiting --> Terminated Trial primary completion date: Jun 2016 --> Dec 2016
- | ZEMBRACE SymTouch (sumatriptan succinate) / Tonix
Trial completion: Pilot Study of Two Different Strengths of DFN-11 Injection for Rapidly Escalating Migraine (clinicaltrials.gov) - Jul 11, 2016
P2, N=20, Completed, Sponsor: Dr. Reddy's Laboratories Limited
Trial primary completion date: Jun 2016 --> Dec 2016 Recruiting --> Completed
- | ZEMBRACE SymTouch (sumatriptan succinate) / Tonix
New P2 trial: Pilot Study of Two Different Strengths of DFN-11 Injection for Rapidly Escalating Migraine (clinicaltrials.gov) - Oct 22, 2015
P2, N=20, Recruiting, Sponsor: Dr. Reddy's Laboratories Limited
- | ZEMBRACE SymTouch (sumatriptan succinate) / Tonix
New P2 trial: Pilot Study of DFN-11 Injection in Medication Overuse Headache (clinicaltrials.gov) - Oct 22, 2015
P2, N=20, Recruiting, Sponsor: Dr. Reddy's Laboratories Limited
- |||||||||| ZEMBRACE SymTouch (sumatriptan succinate) / Tonix
New P3 trial: RESTOR: DFN-11 Injection in Episodic Migraine With or Without Aura (clinicaltrials.gov) - Oct 7, 2015
P3, N=266, Recruiting, Sponsor: Dr. Reddy's Laboratories Limited